A thermostability-enhanced formate dehydrogenase mutant and its application
By substituting multiple amino acid sequences into HceFDH, the thermal stability and catalytic activity of formate dehydrogenase were improved, solving the problem of insufficient NADH supply in existing formate dehydrogenases at high temperatures, and realizing efficient NADH regeneration and multi-enzyme coupled catalysis.
Patent Information
- Application Number
- CN202611381966.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-08
- Publication Date
- 2026-11-10
AI Technical Summary
Existing formate dehydrogenases have low activity and insufficient thermal stability, making it difficult to continuously supply NADH during high-temperature and long-term biocatalytic processes, thus limiting their application in NADH-dependent biocatalytic reactions.
By performing multi-point synergistic modification on the formate dehydrogenase HceFDH derived from Hermanssonia centrifuga, especially by replacing the amino acid sequence in the dimer interface region, a recombinant Escherichia coli engineered bacterium was constructed, which improved its thermal stability and catalytic activity.
The obtained formate dehydrogenase mutant HceFDHM10 has a significantly prolonged half-life at 50℃, improved thermal stability, and catalytic activity comparable to the parent compound. It can efficiently catalyze the oxidation of formate and regeneration of NADH, and is suitable for NADH-dependent enzyme-coupled catalytic reactions.
Smart Images

Figure CN123063359A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of bioengineering technology and relates to a formate dehydrogenase mutant with improved thermal stability and its applications. Specifically, it relates to a formate dehydrogenase mutant with improved thermal stability and its applications in NADH regeneration, biocatalysis, and multi-enzyme coupling reactions. Background Technology
[0002] Formate dehydrogenase (FDH) is an important coenzyme regeneration tool that uses formate as a cosubstrate to reduce NAD. + NADH is obtained, and CO2 is generated as a byproduct. Based on whether the active site contains metal ions, FDH is mainly divided into metal ion-dependent FDH and non-metal ion-dependent FDH. Metal ion-dependent FDH contains molybdenum or tungsten cofactors and iron-sulfur clusters, and is mainly found in anaerobic prokaryotes; non-metal ion-dependent FDH does not contain metal ions or other redox active sites, and is widely found in aerobic bacteria, yeast, fungi, and plants. The FDH enzyme catalytic system has the following advantages: (1) the formate has a relatively small molecular weight and is inexpensive; (2) the reaction product is CO2, which is easy to separate; (3) the reaction is almost irreversible. These advantages make it a promising candidate for application in coenzyme regeneration systems.
[0003] However, the low activity and insufficient stability of formate dehydrogenase limit its industrial application. Researchers have explored various protein engineering strategies for the reported formate dehydrogenases. Ni Hanmeng et al. used a semi-rational design method to predict... Cb By modifying the FDH mutation site, a Q197K / I239C hybrid mutant strain was successfully obtained, exhibiting a 31% increase in specific enzyme activity compared to the wild type (Journal of Food and Biotechnology, 2023, 42(10): 1-8). In 2013, through modification... Mycobacterium vaccae N10 Formate dehydrogenase from the source ( Myc FDH conserved motifs were obtained, resulting in NADP... + A new cofactor with high resistance to ECAA inactivation Myc FDH variants, including the tetra mutant Myc FDH C145S / A198G / D221Q / C255V The half-life in 20 mM ECAA exceeds 172 ± 24 hours. Appl. Microbiol. Biotechnol. , 2013, 97(6): 2473-2481.). Reported in 2021. Cb The effect of three key residues in the FDH substrate binding pocket, Phe285, Gln287, and His311, on enzyme stability compared to the wild type ( T m(at 64℃), mutants His311Gln, Gln287Glu, and Phe285Thr / His311Gln T m The temperatures increased by 13, 16, and 19 °C, respectively, but the improved thermal stability was accompanied by a significant decrease in catalytic activity. Appl. Microbiol. Biotechnol. , 2021, 193(2): 363-376).
[0004] Patent CN111996157A uses formate dehydrogenase as a coenzyme regenerating enzyme, coupled with propylene glycol oxidoreductase to efficiently produce 1,3-propylene glycol, but the activity of the formate dehydrogenase used is only 0.45 U / mg. Patent CN104561052A reports a recombinant formate dehydrogenase with a specific activity of 1.05 U / mg. Patent CN113717954A describes how Jiangnan University modified the molecular structure of formate dehydrogenase using semi-rational design and site-directed mutagenesis to obtain a mutant enzyme K21P / K22R with improved stability. The mutant enzyme K21P / K22R retains more than 80% of its activity after incubation at 65℃ for 60 min, while the parent enzyme is completely inactivated after incubation at 65℃ for 30 min. T m The value was only 4.5℃ higher than the parent. Patent CN106479988A introduces disulfide bonds through protein engineering, making... Cb The activity of FDH was increased by 1.3 times and the half-life at 60°C was increased by 6.8 times, but its half-life was still only 21.6 minutes.
[0005] Due to the high price of NADH, its stoichiometric addition in NADH-dependent biocatalytic reactions would significantly increase production costs. In-situ regeneration of NADH using FDH and inexpensive formate can reduce coenzyme usage; however, FDH is easily inactivated in multi-enzyme systems operating at higher temperatures or for extended periods, leading to insufficient NADH supply and limiting reaction conversion. Therefore, obtaining a formate dehydrogenase mutant possessing both catalytic activity and thermal stability is of great significance for promoting the industrial application of coenzyme regeneration and multi-enzyme coupled biocatalysis. Summary of the Invention
[0006] The present invention aims to overcome the problems of low activity, insufficient thermal stability, and difficulty in continuously supplying NADH in existing formate dehydrogenases during high-temperature and long-term biocatalytic processes, and provides a formate dehydrogenase mutant with improved thermal stability and its application.
[0007] This invention obtains a enzyme derived from enzyme library mining. Hermanssonia centrifugaThe highly active formate dehydrogenase HceFDH, whose amino acid sequence is shown in SEQ ID No. 1, was used to construct a recombinant Escherichia coli strain capable of expressing the formate dehydrogenase HceFDH. However, the formate dehydrogenase HceFDH has poor thermal stability, which severely limits its further industrial application. Therefore, this invention continues to use HceFDH as the starting material to improve its thermal stability.
[0008] The formate dehydrogenase mutant of the present invention was obtained by multi-point synergistic modification of the interface region of the formate dehydrogenase HceFDH dimer, and can be used for in-situ regeneration of NADH and NADH-dependent enzyme-coupled catalytic reactions.
[0009] The objective of this invention can be achieved through the following technical solutions: One of the technical solutions of the present invention is to provide a formate dehydrogenase mutant.
[0010] In some embodiments of the present invention, the parent formate dehydrogenase HceFDH is derived from *Varicella hupensis* (…). Hermanssonia centrifuga The amino acid sequence is shown in SEQ ID No. 1. This gene edits the formate dehydrogenase HceFDH. HceFDH The sequence is shown in SEQ ID No. 2.
[0011] In some embodiments of the present invention, the formate dehydrogenase mutant is a protein corresponding to a new amino acid sequence formed by replacing multiple amino acid residues in the amino acid sequence shown in SEQ ID No. 1 at positions 12, 13, 16, 149, 151, 152, 154, 155, 156, 260, 261, 262, 263, 264, 265, 266, 297, 300, 301, and 305 with other amino acid residues.
[0012] Specifically, the amino acid sequence of the formate dehydrogenase mutant is one of the following: (1) Replace Asn at position 12 with Glu, Ala at position 13 with Trp, and Glu at position 16 with Ala in the amino acid sequence shown in SEQ ID No.1; (2) Replace Asn at position 12 of the amino acid sequence shown in SEQ ID No.1 with Glu, Ala at position 13 with Phe, and Glu at position 16 with Arg; (3) Replace Gln at position 149 with Asp, Ser at position 151 with Ala, Asp at position 152 with Ala, Ala at position 154 with Thr, Arg at position 155 with Cys, and Asn at position 156 with Ser. (4) Replace Gln at position 149 with Asp, Ser at position 151 with Ala, Asp at position 152 with Ala, Ala at position 154 with Ser, and Asn at position 156 with Asp in the amino acid sequence shown in SEQ ID No.1. (5) Replace Ala at position 260 of the amino acid sequence shown in SEQ ID No.1 with Cys, Ala at position 262 with Thr, and Val at position 265 with Ile; (6) Replace Ala at position 260 with Val, Asn at position 261 with Asp, Ala at position 262 with Thr, Glu at position 263 with Asp, Asp at position 264 with Ala, and Ala at position 266 with Val in the amino acid sequence shown in SEQ ID No.1; (7) Replace Leu at position 300 of the amino acid sequence shown in SEQ ID No.1 with Tyr, and replace Asn at position 301 with Gly; (8) Replace Leu at position 300 of the amino acid sequence shown in SEQ ID No.1 with Tyr, Asn at position 301 with Gly, and Gly at position 305 with Ala; (9) Replace Lys at position 297 with Arg, Leu at position 300 with Phe, and Asn at position 301 with Gly in the amino acid sequence shown in SEQ ID No.1; (10) Replace the 12th position Asn with Glu, the 13th position Ala with Phe, the 16th position Glu with Arg, the 149th position Gln with Asp, the 151st position Ser with Ala, the 152nd position Asp with Ala, the 154th position Ala with Ser, the 156th position Asn with Asp, the 260th position Ala with Cys, the 262nd position Ala with Thr, the 265th position Val with Ile, the 300th position Leu with Tyr, and the 301st position Asn with Gly.
[0013] In some preferred embodiments of the present invention, the formate dehydrogenase mutant is specifically selected from the mutant numbered (10), that is, the 12th position Asn of the amino acid sequence shown in SEQ ID No.1 is replaced with Glu, the 13th position Ala is replaced with Phe, the 16th position Glu is replaced with Arg, the 149th position Gln is replaced with Asp, the 151st position Ser is replaced with Ala, the 152nd position Asp is replaced with Ala, the 154th position Ala is replaced with Ser, the 156th position Asn is replaced with Asp, the 260th position Ala is replaced with Cys, the 262nd position Ala is replaced with Thr, the 265th position Val is replaced with Ile, the 300th position Leu is replaced with Tyr, and the 301st position Asn is replaced with Gly.
[0014] The preparation method of the formate dehydrogenase mutant described in this invention is conventional in the art: preferably, firstly, a recombinant bacterium containing HceFDH is constructed, and the HceFDH gene is cloned into plasmid pET-28a to construct the parent recombinant plasmid pET28a- HceFDH This method achieves soluble expression of the target protein, with a histidine tag attached to the C-terminus. A site-directed mutagenesis strategy based on rational design was employed to mutate the parent protein. Through kinetic parameter determination and half-life screening, a formate dehydrogenase mutant with significantly improved stability was obtained. Furthermore, replacing other amino acid residues in the amino acid sequence shown in SEQ ID NO.1 with other amino acid residues that do not affect the catalytic performance of the formate dehydrogenase mutant also falls within the scope of this invention.
[0015] The protein preparation method described in this invention can also be obtained by artificially synthesizing protein sequences.
[0016] The second technical solution of the present invention is to provide a nucleic acid encoding a formate dehydrogenase mutant.
[0017] The nucleic acid is a DNA molecule encoding the formate dehydrogenase mutant described in technical scheme one.
[0018] In some embodiments of the present invention, the nucleotide sequence encoding the formate dehydrogenase mutant is the same as the nucleotide sequence encoding the formate dehydrogenase mutant as described in technical solution one.
[0019] The method for obtaining the encoding nucleic acid of the formate dehydrogenase mutant described in this invention is conventional in the art: preferably, it is obtained by modifying the maternal HceFDH through site-directed mutagenesis, error-prone PCR, or DNA shuffling using genetic engineering techniques, or by artificial full-sequence synthesis.
[0020] The third technical solution of the present invention is to provide a recombinant expression vector, wherein the recombinant expression vector contains the nucleic acid encoding the formate dehydrogenase mutant as described in technical solution two.
[0021] In some embodiments of the present invention, the recombinant expression vector can be constructed by linking the coding nucleic acid sequence of the formate dehydrogenase mutant gene of the present invention to various suitable vectors using conventional methods in the art. The vector can be any conventional vector in the art, preferably the pET-28a plasmid.
[0022] Preferably, the recombinant expression vector of the present invention can be prepared by the following method: using the recombinant plasmid pET28a- HceFDH Using a template, full-plasmid PCR was performed with mutation-specific primers to construct site-directed mutagenesis and obtain a linearized full-plasmid product containing the mutation site. After the PCR product was digested and degraded by Dpn I, it was transformed into E. coli BL21(DE3) competent cells, plated, and positive clones were screened. After sequencing verification, a recombinant expression vector containing the formate dehydrogenase mutant encoding nucleic acid sequence was obtained.
[0023] The fourth technical solution of the present invention is to provide a recombinant expression transformant.
[0024] The recombinant expression transformant comprises the nucleic acid encoding the formate dehydrogenase mutant as described in technical solution 2 or the recombinant expression vector as described in technical solution 3.
[0025] In some embodiments of the present invention, the host microorganism of the recombinant expression transformant is Escherichia coli.
[0026] The recombinant expression transformant can be prepared by introducing the recombinant expression vector of the present invention into host cells using conventional methods in the art. The host cell is a conventional host cell in the art, provided that the recombinant expression vector can stably replicate spontaneously and that the nucleic acid sequence encoding the formate dehydrogenase mutant carried by it can be effectively expressed; preferably, it is *Escherichia coli* BL21(DE3). Transforming the recombinant expression vector into *Escherichia coli* BL21(DE3) yields the preferred genetically engineered strain of the present invention.
[0027] The fifth technical solution of the present invention is: to provide a recombinant formate dehydrogenase catalyst, wherein the recombinant formate dehydrogenase mutant catalyst comprises any one of the following forms: (1) Culture the recombinant expression transformant and isolate the transformant cells containing the formate dehydrogenase mutant; (2) Cultivate the recombinant expression transformant and isolate the crude enzyme solution containing the formate dehydrogenase mutant; (3) Cultivate the recombinant expression transformant, separate the crude enzyme solution containing the formate dehydrogenase mutant, and freeze-dry the crude enzyme powder obtained; (4) Cultivate the recombinant expression transformant, separate the crude enzyme solution containing the formate dehydrogenase mutant, and purify the obtained pure enzyme solution.
[0028] This invention also provides a method for preparing a recombinant formate dehydrogenase mutant catalyst, comprising culturing the recombinant expression transformant as described in technical scheme four, collecting the transformant cells and obtaining a crude enzyme solution through disruption and solid-liquid separation, or further purifying or freeze-drying the crude enzyme solution to obtain the corresponding form of recombinant formate dehydrogenase catalyst. The culture conditions of the recombinant expression transformant can employ conventional methods in the art.
[0029] In some embodiments, a preferred culture method for recombinant *E. coli* is as follows: the recombinant *E. coli* constructed as described above is inoculated into LB medium containing 100 μg / mL kanamycin (10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride), and cultured at 37°C. o C, incubate at 220 rpm, when the OD of the culture medium... 600 To reach a concentration of 0.6–0.8, add isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.2 mM, at 200 rpm, for 16 minutes. o Cells were induced with C for 20 h to express the target protein. Cells were collected by centrifugation at 12000 rpm for 5 min, and resuspended at 10 mL / g in potassium phosphate buffer (KPB, 100 mM, pH 7.0). Cells were then lysed by sonication and expressed at 4... o Cell debris was removed by centrifugation at 12,000 rpm for 50 minutes at C. The crude enzyme solution of the recombinant formate dehydrogenase mutant was then obtained.
[0030] The sixth technical solution of the present invention is: providing the formate dehydrogenase mutant or recombinant formate dehydrogenase catalyst in NAD... + Applications of NADH in-situ recycling system.
[0031] The NAD + The NADH in-situ recycling system consists of NADH regeneration and NADH-dependent enzyme-coupled catalytic reactions.
[0032] In some embodiments of the present invention, in formate and NAD + Under the present conditions, the formate dehydrogenase mutant catalyzes the oxidation of formate to CO2, while simultaneously converting NAD+. + The NADH is reduced to NADH; the generated NADH is used by NADH-dependent enzymes and regenerated into NAD in downstream reactions. + Thus forming NAD + / NADH in-situ recycling system.
[0033] In some embodiments of the present invention, the NADH-dependent enzyme is selected from monooxygenases, dehydrogenases, or reductases, preferably cyclohexanone monooxygenase or 7β-hydroxysteroid dehydrogenase.
[0034] In some preferred embodiments of the present invention, the formate dehydrogenase mutant is coupled with cyclohexanone monooxygenase to synthesize ε-caprolactone using cyclohexanone as a substrate. In some preferred embodiments of the present invention, the formate dehydrogenase mutant is coupled with 7β-hydroxysteroid dehydrogenase to synthesize ursodeoxycholic acid using 7-ketolithocholic acid as a substrate.
[0035] In some embodiments of the present invention, the catalytic reaction is carried out in a phosphate buffer solution containing 0.05-0.2 mol / L and pH 6.0-8.0; the formate is sodium formate with a concentration of 10-800 mmol / L; NAD + Concentration: 0.1-1 mmol / L; Reaction temperature: 25-50 °C o C.
[0036] The method for determining the activity of the formate dehydrogenase mutant described in this invention involves: mixing sodium formate containing 100 mmol / L and NAD+. + The 1 ml reaction mixture (100 mmol / L potassium phosphate buffer, pH=7.0) was preheated to 30 °C. o C, then add an appropriate amount of formate dehydrogenase mutant, 30 o The reaction was carried out at temperature C. The absorbance change of NADH at 340 nm was detected on a spectrophotometer, and the absorbance change value within 1 minute was recorded.
[0037] The enzyme activity can be calculated using the following formula (referencing Beer-Lambert Law): Enzyme activity (U) = EW × V × 10 3 / (6220×l) In the formula, EW is the change in absorbance at 340 nm within 1 minute; V is the volume of the reaction solution in mL; 6220 is the molar extinction coefficient of NADH at 340 nm in L / (mol·cm); and l is the optical path distance in cm. One unit of enzyme activity (U) is defined as the amount of enzyme required to catalyze the production of 1 μmol of NADH per minute under the above conditions.
[0038] Specific activity (U / mg) = U / m 酶 In the formula, m 酶 The amount of enzyme solution added is in mg.
[0039] The method for determining the half-life of the formate dehydrogenase mutant described in this invention is as follows: The protein concentration of the recombinant formate dehydrogenase mutant is diluted to 1 mg / mL. 1 mg of the purified enzyme is placed in a 50°C water bath and incubated. Samples are taken at 0, 0.5, 1, 2, 4, 8, 12, 18, 24, and 48 h, and immediately cooled on ice for 5 min before measuring the remaining specific activity. The initial enzyme activity measured at 0 min is taken as 100%, and the relative enzyme activity of the samples at each time point after heat treatment is calculated to determine the thermostability of the mutant enzyme.
[0040] By fitting a linear curve with the incubation time t as the x-axis and the logarithm of residual activity Ln (residual activity%) as the y-axis, the deactivation constant k can be obtained. d Half-life t 1 / 2 (50 o C)=Ln2 / k d .
[0041] The melting temperature of the formate dehydrogenase mutant described in this invention ( T m The protein was determined by circular dichroism (CD) spectroscopy. The initial protein sample was diluted to 0.4 mg / mL with 100 mM sodium phosphate buffer (pH 7.0). -1 Subsequently, the diluted protein samples were placed in cuvettes with an optical path of 0.2 cm and detected using a Chirascan circular dichroism spectrometer. The range was 20–90 °C. o Within range C, with 2 o C represents the temperature interval, 2 o The heating rate was set at C / min, and CD spectra in the range of 190–280 nm (step size 1 nm) were recorded. Subsequently, Global 3 analysis software was used to perform global fitting analysis on the protein CD spectra obtained at different temperatures to obtain the calculated Tc. m value.
[0042] This invention employs gas chromatography for qualitative and quantitative analysis of cyclohexanone and ε-caprolactone in the reaction system. A CP-type capillary column is used with nitrogen as the carrier gas at a flow rate of 3 mL / min. The column temperature program is as follows: initial temperature 50 °C. o C, hold for 1 minute; at 20 o Heat to 120°C / min o C, hold for 2 minutes; then at 20 o Temperature increased to 180 °C / min oC, hold for 2 min. Qualitative analysis was performed based on the retention times of cyclohexanone and ε-caprolactone standards, and quantification was performed based on standard curves established using the concentrations of cyclohexanone and ε-caprolactone and their corresponding peak areas. The yield of ε-caprolactone was calculated using the following formula: ε-caprolactone yield (%) = (molar amount of ε-caprolactone / molar amount of cyclohexanone at the start of the reaction) × 100%.
[0043] The synthesis conditions for ε-caprolactone were as follows: the total reaction volume was 1 mL, and the reaction system contained 10 mM cyclohexanone and 1 mM NAD. + 100 mM sodium formate, 0.01 mg purified HceFDH M10 and 0.2 mg of purified AcCHMO 9871 The reaction system was prepared using 100 mM potassium phosphate buffer solution at pH 7.0. The reaction was carried out at 40°C. o The reaction was carried out at 200 rpm under continuous oxygen supply conditions. During the reaction, HceFDH... M10 Catalyze the oxidation of sodium formate and NAD + Restored to NADH, AcCHMO 9871 The generated NADH is used to catalyze the oxidation of cyclohexanone to ε-caprolactone, while simultaneously regenerating NAD. + This leads to the formation of NAD. + / NADH in-situ circulation.
[0044] This invention employs high-performance liquid chromatography (HPLC) to determine the content of residual 7-oxo-LCA in the reaction system. The chromatographic column is an ODS-2 reversed-phase column (250 mm × 4.6 mm, 5 μm particle size, Elite). The mobile phase is methanol and an aqueous solution containing 0.005% phosphoric acid at a volume ratio of 75:25, using isocratic elution. The flow rate is 0.8 mL / min, and the column temperature is 30 °C. o C. The detection wavelength is 280 nm. Qualitative analysis is performed based on the retention time of the 7-oxo-LCA standard, and quantitative analysis is performed based on a standard curve established using the 7-oxo-LCA concentration and the corresponding peak area. The 7-oxo-LCA conversion rate is calculated using the following formula: 7-oxo-LCA conversion rate (%) = (molar amount of 7-oxo-LCA before reaction - molar amount of 7-oxo-LCA remaining after reaction) / molar amount of 7-oxo-LCA before reaction × 100%.
[0045] The synthesis reaction conditions for ursodeoxycholic acid are as follows: the total reaction volume is 1 mL, and the reaction system contains 10 mM 7-oxo-LCA and 1 mM NAD. + 100 mM sodium formate, 0.1 mg purified HceFDH M10And 0.02 mg of purified 7β-hydroxysteroid dehydrogenase, prepared in a reaction system using 100 mM potassium phosphate buffer at pH 8. The reaction was carried out at 50°C and 200 rpm. During the reaction, HceFDH... M10 Catalyzes the oxidation of sodium formate, while simultaneously releasing NAD. + 7β-HSDH uses the generated NADH to reduce 7-oxo-LCA to ursodeoxycholic acid, while simultaneously regenerating NAD. + This leads to the formation of NAD. + / NADH in-situ recycling system.
[0046] The reaction or detection conditions described in this invention can be combined or modified based on common knowledge in the field, and verified through experiments.
[0047] Unless otherwise specified, all raw materials or reagents used in this invention are commercially available.
[0048] Compared with the prior art, the present invention has the following advantages: (1) The formate dehydrogenase mutant provided by the present invention has a specific enzyme activity of 7.81 U / mg, which is higher than that of similar formate dehydrogenases such as CbFDH, and can efficiently catalyze the oxidation of formate and regenerate NADH.
[0049] (2) The formate dehydrogenase mutant provided by this invention has significantly improved thermostability compared to the parent HceFDH. Among them, the mutant HceFDH... M10 of T m The value was 61.7℃, which was 8.6℃ higher than that of the parent. At the same time, the half-life of this mutant at 50℃ was extended by 100 to 500 times compared with the parent, while maintaining a specific enzyme activity comparable to that of the parent, thus alleviating the common problem of activity loss during the stability improvement process.
[0050] (3) HceFDH M10 It can be used for in-situ NADH recycling at higher temperatures and can be coupled with NADH-dependent enzymes to form a catalytic system. In the embodiments of the present invention, it is respectively at 40°C. o C and 50 o Under C conditions, the reaction of cyclohexanone monooxygenase and 7β-hydroxysteroid dehydrogenase was driven, and the yield of ε-caprolactone reached 99% while the conversion of 7-ketolithocholic acid reached 95%, indicating that this mutant has the potential for application in multi-enzyme catalysis and the synthesis of high-value-added compounds. Attached Figure Description
[0051] Figure 1 The thermostability of the parent and mutant enzymes at 50°C. Detailed Implementation
[0052] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments. These embodiments are based on the technical solution of the present invention and provide detailed implementation methods and specific operating procedures. However, the scope of protection of the present invention is not limited to the following embodiments.
[0053] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.
[0054] Unless otherwise stated, the reagents used in the following examples are commercially available products, and the specific experiments were conducted in accordance with conventional methods and conditions in the art, or in accordance with the product instructions of the kit.
[0055] The materials used in the following embodiments are sourced from: Parental recombinant plasmid pET28a- HceFDH It contains the nucleic acid sequence shown in SEQ ID No. 2, which was artificially synthesized by the inventor. HceFDH Using the gene plasmid as a template, a fragment of formate dehydrogenase was amplified by full plasmid PCR reaction using primers HceFDH-F (GCCATATGAAAATTATCGCGGTGCTTTACA SEQ ID No.11) and HceFDH-P (GTGGTGTCGTTTACCATACGAGCCCGTCTC SEQ ID No.12), obtaining the complete nucleic acid molecule encoding HceFDH, which was then ligated into the pET28a plasmid to construct the gene.
[0056] PrimeSTAR Max DNA Polymerase was purchased from Bio-Tech Biotechnology (Beijing) Co., Ltd., and the agarose gel DNA recovery kit was purchased from Beijing Tiangen Biotech Co., Ltd.
[0057] The restriction endonucleases Dpn I and Sac I are both commercially available products from New England Biolabs (NEB).
[0058] Example 1: Construction of formate dehydrogenase mutant The nucleotide sequence encoding formate dehydrogenase, as shown in SEQ ID No. 2, was subjected to multi-point co-mutation using whole plasmid PCR. The synthetic primers involved in the preferred mutant (10) are shown in Table 1 (underlined are mutation sites).
[0059] Table 1 Primer sequences for mutations pET28a-HceFDH Alternatively, using a previously sequenced and validated mutant plasmid as a template, perform full-plasmid PCR with PrimeSTAR Max DNAPolymerase to construct a site-directed mutagen. PCR system (50 μL): PrimeSTAR Max DNAPolymerase 25 μL, forward and reverse primers (10 μM) 1 μL each, pET28a- HceFDH Add 1 μL of plasmid (1 ng / μL) and sterile distilled water to a final volume of 50 μL. PCR reaction procedure: (1) 98 o C pre-denaturation 2 min; (2) 98 o C denaturation for 10 s; (3) 55 o C annealing for 15 seconds; (4) 72 o C extends for 120 seconds; steps (2)-(4) are performed for a total of 24 cycles; (5) 72 o C extends for 7 minutes; (6) 4 o C preserves the product.
[0060] After verifying the correctness of the PCR product by 1% agarose gel electrophoresis (9 μL), the target product was recovered and electrophoresed with Dpn I at 37°C. o Digestion at 37°C for 1 h was used to remove methylated template plasmids, and the treated product was then transformed into *E. coli* BL21(DE3) competent cells. The transformation solution was plated on LB solid medium containing 100 μg / mL kanamycin and incubated at 37°C. o Culture at 37°C for 16-24 h; pick 1-3 transformants and inoculate them into LB liquid medium containing 100 μg / mL kanamycin, incubate at 37°C. o C. Incubate overnight at 180 rpm and perform sequencing verification. For HceFDH containing multiple segregated mutant regions... M10 The next set of mutations is introduced sequentially using the mutated plasmid that was correctly sequenced in the previous round as a template until a recombinant expression plasmid containing all 13 amino acid substitutions is obtained.
[0061] Example 2: Expression of recombinant formate dehydrogenase mutant The mutant strain obtained in Example 1 was inoculated into LB liquid medium containing 100 μg / mL kanamycin (10 g / L tryptone, 5 g / L yeast extract, 10 g / L glucose), and incubated at 37°C. o Culturing at 220 rpm for 12 h at C. Cells were then inoculated at a 1% seed volume in LB medium containing 100 μg / mL kanamycin until the bacterial culture reached OD500. 600 When the concentration is 0.6-0.8, add 20 μL of isopropyl-β-D-thiopyranogalactopyranoside (IPTG) to a final concentration of 0.2 mM, at 200 rpm, for 16 minutes. oCells were cultured at C20°C for 20 h to express the target protein. Cells were collected by centrifugation at 12000 rpm for 5 min and resuspended in 10 mL of potassium phosphate buffer (KPB, 100 mM, pH 7.0). Cells were lysed by sonication and expressed at 4°C. o Cell debris was removed by centrifugation at 12,000 rpm for 50 minutes at C. Proteins were purified using a self-filled HisTrap HF (GE Healthcare, USA, 4 mL bed) gel gravity column.
[0062] Example 3: HceFDH M10 Determination of specific activity A mixture containing 100 mmol / L sodium formate and 1 mmol / L NAD + A 1 ml reaction system (0.1 mol / L potassium phosphate buffer, pH 7.0) was preheated to 30°C, and then 0.01 mg of formate dehydrogenase mutant was added. The reaction was incubated at 30°C, and the absorbance change of NADH at 340 nm was detected on a spectrophotometer. The absorbance change value within 1 minute was recorded. The enzyme activity calculation formula (referring to Lambert-Beer's law) is: Enzyme activity (U) = EW × V × 10³ / (6220 × l). Where, EW is the change of absorbance at 340 nm within 1 minute; V is the volume of the reaction solution in mL; 6220 is the molar extinction coefficient of NADH in L / (mol·cm); l is the optical path distance in cm. One unit of enzyme activity (U) is defined as the amount of enzyme required to catalyze the production of 1 μmol of NADH per minute under the above conditions, and the measured HceFDH. M10 Its specific activity was 7.81 U / mg, comparable to that of the wild type.
[0063] Example 4: Half-life determination of recombinant formate dehydrogenase mutant The protein concentration of the recombinant formate dehydrogenase mutant was diluted to 1 mg / mL. One mg of the purified enzyme was placed in a 50°C water bath and incubated. Samples were taken at 0, 0.5, 1, 2, 4, 8, 12, 18, 24, and 48 h, and immediately cooled on ice for 5 min before measuring the remaining specific activity. The initial enzyme activity measured at 0 min was taken as 100%, and the relative enzyme activity of the samples at each heat-treated time point was calculated to determine the thermostability of the mutant enzyme.
[0064] By fitting a linear curve with the incubation time (h) on the x-axis and the logarithm of the residual activity (Ln) on the y-axis, the inactivation constant k can be obtained. d Half-life t1 / 2 (50℃) = Ln2 / k d .
[0065] In the list of Table 2, the sequence numbers refer to the corresponding sequences following Table 2. In t 1 / 2 In the "(50℃) increase factor" column, compared with the parent HceFDH, "+" indicates that the half-life is increased by 1 to 10 times; "++" indicates that the half-life is increased by 10 to 100 times; "++++" indicates that the half-life is increased by 100 to 500 times.
[0066] Table 2 Recombinant formate dehydrogenase mutants and their 50 o The factor that increases the C half-life The amino acid sequences of the formate dehydrogenase mutants corresponding to the sequence numbers are as follows: (1) Replace Asn at position 12 with Glu, Ala at position 13 with Trp, and Glu at position 16 with Ala in the amino acid sequence shown in SEQ ID No.1; (2) Replace Asn at position 12 of the amino acid sequence shown in SEQ ID No.1 with Glu, Ala at position 13 with Phe, and Glu at position 16 with Arg; (3) Replace Gln at position 149 with Asp, Ser at position 151 with Ala, Asp at position 152 with Ala, Ala at position 154 with Thr, Arg at position 155 with Cys, and Asn at position 156 with Ser. (4) Replace Gln at position 149 with Asp, Ser at position 151 with Ala, Asp at position 152 with Ala, Ala at position 154 with Ser, and Asn at position 156 with Asp in the amino acid sequence shown in SEQ ID No.1. (5) Replace Ala at position 260 of the amino acid sequence shown in SEQ ID No.1 with Cys, Ala at position 262 with Thr, and Val at position 265 with Ile; (6) Replace Ala at position 260 with Val, Asn at position 261 with Asp, Ala at position 262 with Thr, Glu at position 263 with Asp, Asp at position 264 with Ala, and Ala at position 266 with Val in the amino acid sequence shown in SEQ ID No.1; (7) Replace Leu at position 300 of the amino acid sequence shown in SEQ ID No.1 with Tyr, and replace Asn at position 301 with Gly; (8) Replace Leu at position 300 of the amino acid sequence shown in SEQ ID No.1 with Tyr, Asn at position 301 with Gly, and Gly at position 305 with Ala; (9) Replace Lys at position 297 with Arg, Leu at position 300 with Phe, and Asn at position 301 with Gly in the amino acid sequence shown in SEQ ID No.1; (10) Replace the 12th position Asn with Glu, the 13th position Ala with Phe, the 16th position Glu with Arg, the 149th position Gln with Asp, the 151st position Ser with Ala, the 152nd position Asp with Ala, the 154th position Ala with Ser, the 156th position Asn with Asp, the 260th position Ala with Cys, the 262nd position Ala with Thr, the 265th position Val with Ile, the 300th position Leu with Tyr, and the 301st position Asn with Gly.
[0067] Example 5: HceFDH M1 of T m Value determination HceFDH M1 melting temperature ( T m The protein was determined by circular dichroism (CD) spectroscopy. The initial protein sample was diluted to 0.4 mg / mL with 100 mM sodium phosphate buffer (pH 7.0). -1 Subsequently, the diluted protein samples were placed in cuvettes with an optical path of 0.2 cm and detected using a Chirascan circular dichroism spectrometer. The range was 20–90 °C. o Within range C, with 2 o C represents the temperature interval, 2 o The CD spectra were recorded in the range of 190–280 nm (step size 1 nm) at a heating rate of C / min. Subsequently, Global 3 analysis software was used to perform global fitting analysis on the protein CD spectra obtained at different temperatures to obtain the calculated values. T m Value. Wild-type HceFDH T m It is 53.1 o C, mutant enzyme HceFDH M1 of T m It is 55.2 o C, 2.1 higher than wild type. o C.
[0068] Example 6: HceFDH M3 of T m Value determination HceFDH M3 melting temperature ( T m The protein was determined by circular dichroism (CD) spectroscopy. The initial protein sample was diluted to 0.4 mg / mL with 100 mM sodium phosphate buffer (pH 7.0). -1 Subsequently, the diluted protein samples were placed in cuvettes with an optical path of 0.2 cm and detected using a Chirascan circular dichroism spectrometer. The range was 20–90 °C. o Within range C, with 2 o C represents the temperature interval, 2 o The CD spectra were recorded in the range of 190–280 nm (step size 1 nm) at a heating rate of C / min. Subsequently, Global 3 analysis software was used to perform global fitting analysis on the protein CD spectra obtained at different temperatures to obtain the calculated values. T m Value. Mutant enzyme HceFDH M3 of T m It is 57.4 o C, 4.3 higher than wild type. o C.
[0069] Example 7: HceFDH M5 of T m Value determination HceFDH M5 melting temperature ( T m The protein was determined by circular dichroism (CD) spectroscopy. The initial protein sample was diluted to 0.4 mg / mL with 100 mM sodium phosphate buffer (pH 7.0). -1 Subsequently, the diluted protein samples were placed in cuvettes with an optical path of 0.2 cm and detected using a Chirascan circular dichroism spectrometer. The range was 20–90 °C. o Within range C, with 2 o C represents the temperature interval, 2 o The CD spectra were recorded in the range of 190–280 nm (step size 1 nm) at a heating rate of C / min. Subsequently, Global 3 analysis software was used to perform global fitting analysis on the protein CD spectra obtained at different temperatures to obtain the calculated values. T m Value. Mutant enzyme HceFDHM5 of T m It is 56.9 o C, 3.8 higher than wild type. o C.
[0070] Example 8: HceFDH M7 of T m Value determination HceFDH M7 melting temperature ( T m The protein was determined by circular dichroism (CD) spectroscopy. The initial protein sample was diluted to 0.4 mg / mL with 100 mM sodium phosphate buffer (pH 7.0). -1 Subsequently, the diluted protein samples were placed in cuvettes with an optical path of 0.2 cm and detected using a Chirascan circular dichroism spectrometer. The range was 20–90 °C. o Within range C, with 2 o C represents the temperature interval, 2 o The CD spectra were recorded in the range of 190–280 nm (step size 1 nm) at a heating rate of C / min. Subsequently, Global 3 analysis software was used to perform global fitting analysis on the protein CD spectra obtained at different temperatures to obtain the calculated values. T m Value. Mutant enzyme HceFDH M7 of T m It is 58.7 o C, increased by 5.6 compared to the wild type. o C.
[0071] Example 9: HceFDH M10 of T m Value determination HceFDH M10 melting temperature ( T m The protein was determined by circular dichroism (CD) spectroscopy. The initial protein sample was diluted to 0.4 mg / mL with 100 mM sodium phosphate buffer (pH 7.0). -1 Subsequently, the diluted protein samples were placed in cuvettes with an optical path of 0.2 cm and detected using a Chirascan circular dichroism spectrometer. The range was 20–90 °C. o Within range C, with 2 o C represents the temperature interval, 2 oThe CD spectra were recorded in the range of 190–280 nm (step size 1 nm) at a heating rate of C / min. Subsequently, Global 3 analysis software was used to perform global fitting analysis on the protein CD spectra obtained at different temperatures to obtain the calculated values. T m Value. Mutant enzyme HceFDH M10 of T m It is 61.7 o C, increased by 8.6 compared to the wild type. o C.
[0072] Example 10: HceFDH at 40℃ M10 The synthesis of ε-caprolactone catalyzed by coupling with cyclohexanone monooxygenase Cyclohexanone monooxygenase (CHMO) can generate ε-caprolactone via Baeyer-Villiger oxidation using cyclohexanone as a substrate, in the presence of reduced coenzyme NADH and oxygen. To verify the formate dehydrogenase mutant HceFDH obtained in this invention... M10 Performance of HceFDH as a NADH regenerator under higher temperature conditions M10 AcCHMO, a NADH-dependent cyclohexanone monooxygenase mutant 9871 To carry out a coupling reaction.
[0073] The total reaction volume was 1 mL, and the reaction system contained 10 mM cyclohexanone and 1 mM NAD. + 100 mM sodium formate, 0.01 mg purified HceFDH M10 and 0.2 mg of purified AcCHMO 9871 The reaction system was prepared using 100 mM potassium phosphate buffer solution at pH 7.0. The reaction was carried out at 40°C. o The reaction was carried out at 200 rpm under continuous oxygen supply conditions. During the reaction, HceFDH... M10 Catalyze the oxidation of sodium formate and NAD + Restored to NADH, AcCHMO 9871 The generated NADH is used to catalyze the oxidation of cyclohexanone to ε-caprolactone, while simultaneously regenerating NAD. + This leads to the formation of NAD. + / NADH in-situ circulation.
[0074] Gas chromatography was used for qualitative and quantitative analysis of cyclohexanone and ε-caprolactone in the reaction system. A CP capillary column was used with nitrogen as the carrier gas at a flow rate of 3 mL / min. The column temperature program was as follows: initial temperature 50 °C. o C, hold for 1 minute; at 20 oHeat to 120°C / min o C, hold for 2 minutes; then at 20 o Temperature increased to 180 °C / min o C, hold for 2 min. Qualitative analysis was performed based on the retention times of cyclohexanone and ε-caprolactone standards, and quantification was performed based on standard curves established using the concentrations of cyclohexanone and ε-caprolactone and their corresponding peak areas. The yield of ε-caprolactone was calculated using the following formula: ε-caprolactone yield (%) = (molar amount of ε-caprolactone / molar amount of cyclohexanone at the start of the reaction) × 100%.
[0075] After 12 h of reaction, the yield of ε-caprolactone reached 99%, indicating that HceFDH M10 Available at 40 o Under C conditions, NADH is regenerated in situ and used in NADH-dependent monooxygenase catalytic systems.
[0076] Example 11: 50 o HceFDH under C conditions M10 Coupled with 7β-hydroxysteroid dehydrogenase to catalyze the synthesis of ursodeoxycholic acid 7β-hydroxysteroid dehydrogenase (7β-HSDH) can utilize the reduced coenzyme NADH to convert 7-ketolithocholic acid (7-oxo-LCA) to ursodeoxycholic acid (UDCA). To verify the formate dehydrogenase mutant HceFDH obtained in this invention... M10 This embodiment demonstrates the application performance of HceFDH in high-temperature NADH regeneration and steroid compound biotransformation systems. M10 It undergoes a coupling reaction with NADH-dependent 7β-hydroxysteroid dehydrogenase.
[0077] The total reaction volume was 1 mL, and the reaction system contained 10 mM 7-oxo-LCA and 1 mM NAD. + 100 mM sodium formate, 0.1 mg purified HceFDH M10 And 0.02 mg of purified 7β-hydroxysteroid dehydrogenase, were used to prepare the reaction system in 100 mM potassium phosphate buffer, pH=8. The reaction was carried out at 50°C. o The reaction was carried out at 200 rpm (C). During the reaction, HceFDH... M10 Catalyzes the oxidation of sodium formate, while simultaneously releasing NAD. + 7β-HSDH uses the generated NADH to reduce 7-oxo-LCA to ursodeoxycholic acid, while simultaneously regenerating NAD. + This leads to the formation of NAD. + / NADH in-situ recycling system.
[0078] The residual 7-oxo-LCA in the reaction system was determined by high performance liquid chromatography (HPLC). An ODS-2 reversed-phase column (250 mm × 4.6 mm, 5 μm particle size, Elite) was used. The mobile phase consisted of methanol and an aqueous solution containing 0.005% phosphoric acid at a volume ratio of 75:25, with isocratic elution. The flow rate was 0.8 mL / min, and the column temperature was 30 °C. o C. The detection wavelength is 280 nm. Qualitative analysis is performed based on the retention time of the 7-oxo-LCA standard, and quantitative analysis is performed based on a standard curve established using the 7-oxo-LCA concentration and the corresponding peak area. The 7-oxo-LCA conversion rate is calculated using the following formula: 7-oxo-LCA conversion rate (%) = (molar amount of 7-oxo-LCA before reaction - molar amount of 7-oxo-LCA remaining after reaction) / molar amount of 7-oxo-LCA before reaction × 100%.
[0079] After 2 hours of reaction, the conversion rate of 7-oxo-LCA reached 95%, indicating that HceFDH M10 It can be found in 50 o Under C conditions, in-situ regeneration of NADH has the potential to be applied to the biosynthesis of steroidal drug intermediates and other high-value-added compounds.
[0080] The specific details of SEQ ID NO.1 and SEQ ID NO.2 mentioned above are as follows.
[0081] SEQ ID NO.1 (Amino acid sequence of parent HceFDH) MKIIAVLYKG GNAAKEEPRL LGTVENELGL RPWLESQGHE YLVSDDKEGS QSFLNKNIKD 60 ADIVITTPFH PGYLTRELLD TAKNLKVCVT AGVGSDHVDL NAAVDKGLEV LEVTGSNVTS 120 VAEHVVMSML LLVRNFVPAH EMIERGDWQV SDIARNAFDL EGKVIGTIGA GRIGYRVLQR 180 VLPFGPKELV YYDYNALPDA AAKTVGARRI DDLKDFVSQC DVITVNAPLH EGTRNLINAD 240 LLKHFKKGAW LVNTARGAIA NAEDVAAALK SGQLRGYAGD VWNKQPAPKD HPWRYMKNPL 300 NGGNGMVPHY SGTTLDAQKR YADGTRQILE NYFNNKPQEA ANIIVGKKGY ETGSYGKR 358 SEQ ID NO. 2 (Gene sequence of parent HceFDH) atgaaaatta tcgcggtgct ttacaaaggt ggtaacgcag caaaggagga gccgcgttta 60 ctggggaccg tggaaaacga attgggtctg cgtccttggc tggaatcaca gggccacgaa 120 tatttagtga gtgatgataa ggagggttcg cagagttttc tgaataagaa tattaaggat 180 gccgatatcg ttatcactac tcctttccac ccaggctatc tgacccgcga gctgcttgat 240 acggccaaga atttaaaagt gtgtgttacc gcaggggttg gctctgacca tgttgacctg 300 aatgccgccg tggataaagg cttggaggtg ctggaagtga ctggcagcaa tgtcacctcg 360 gtcgcggaac atgtggttat gtccatgctg ctgttggttc gtaactttgt cccggcacat 420 gaaatgattg aacgcggcga ttggcaagtc tccgatattg cacgcaacgc ctttgatctg 480 gaaggcaaag ttattggtac catcggtgct ggtcgtattg gttaccgcgt gctgcagcgc 540 gtcttgcctt ttggtccaaa ggagctggtc tattatgact ataatgccct gccggatgcc 600 gcggcgaaga ccgttggtgc ccgtcgcatt gacgatctga aagacttcgt gagtcagtgc 660 gatgtcatta cggtgaacgc accgctgcac gaagggaccc gtaatttaat caacgcggat 720 cttctgaaac actttaagaa gggcgcatgg ctggtcaata cggcccgcgg cgccattgcg 780 aatgcagaag atgtggcggc agcgctgaaa agcgggcaac ttcgtggcta tgcgggcgat 840 gtgtggaaca agcagcctgc gccgaaagat catccgtggc gttatatgaa gaatccgctg 900 aacggtggta acggcatggt gccacattat tctggcacca cgctggatgc gcagaaacgc 960 tacgcggacg gcacccgcca gatcctggaa aactacttta acaataagcc gcaggaagcc 1020 gcgaacatta ttgttggtaa aaagggctat gagacgggct cgtatggtaa acga 1074 The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.
Claims
1. A formate dehydrogenase mutant, characterized in that, It is a protein composed of any of the following amino acid sequences: (1) Replace Asn at position 12 with Glu, Ala at position 13 with Trp, and Glu at position 16 with Ala in the amino acid sequence shown in SEQ ID No.1; (2) Replace Asn at position 12 with Glu, Ala at position 13 with Phe, and Glu at position 16 with Arg in the amino acid sequence shown in SEQ ID No.1; (3) Replace Gln at position 149 with Asp, Ser at position 151 with Ala, Asp at position 152 with Ala, Ala at position 154 with Thr, Arg at position 155 with Cys, and Asn at position 156 with Ser. (4) Replace Gln at position 149 with Asp, Ser at position 151 with Ala, Asp at position 152 with Ala, Ala at position 154 with Ser, and Asn at position 156 with Asp in the amino acid sequence shown in SEQ ID No.
1. (5) Replace Ala at position 260 of the amino acid sequence shown in SEQ ID No.1 with Cys, Ala at position 262 with Thr, and Val at position 265 with Ile; (6) Replace Ala at position 260 with Val, Asn at position 261 with Asp, Ala at position 262 with Thr, Glu at position 263 with Asp, Asp at position 264 with Ala, and Ala at position 266 with Val in the amino acid sequence shown in SEQ ID No.1; (7) Replace Leu at position 300 of the amino acid sequence shown in SEQ ID No.1 with Tyr, and replace Asn at position 301 with Gly; (8) Replace Leu at position 300 of the amino acid sequence shown in SEQ ID No.1 with Tyr, Asn at position 301 with Gly, and Gly at position 305 with Ala; (9) Replace Lys at position 297 with Arg, Leu at position 300 with Phe, and Asn at position 301 with Gly in the amino acid sequence shown in SEQ ID No.1; (10) Replace the 12th position Asn with Glu, the 13th position Ala with Phe, the 16th position Glu with Arg, the 149th position Gln with Asp, the 151st position Ser with Ala, the 152nd position Asp with Ala, the 154th position Ala with Ser, the 156th position Asn with Asp, the 260th position Ala with Cys, the 262nd position Ala with Thr, the 265th position Val with Ile, the 300th position Leu with Tyr, and the 301st position Asn with Gly.
2. The formate dehydrogenase mutant according to claim 1, characterized in that, The mutant is: The protein is composed of the following amino acid sequences as shown in SEQ ID No. 1: 12th position Asn replaced with Glu, 13th position Ala replaced with Phe, 16th position Glu replaced with Arg, 149th position Gln replaced with Asp, 151st position Ser replaced with Ala, 152nd position Asp replaced with Ala, 154th position Ala replaced with Ser, 156th position Asn replaced with Asp, 260th position Ala replaced with Cys, 262nd position Ala replaced with Thr, 265th position Val replaced with Ile, 300th position Leu replaced with Tyr, and 301st position Asn replaced with Gly.
3. An isolated nucleic acid, characterized in that, The nucleic acid is a DNA molecule encoding the formate dehydrogenase mutant as described in claim 1.
4. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the nucleic acid as described in claim 3.
5. A recombinant expression transformant, characterized in that, The recombinant expression transformant comprises the recombinant expression vector as described in claim 4.
6. The recombinant expression transformant according to claim 5, characterized in that, It is a genetically engineered strain obtained by transforming the recombinant expression vector as described in claim 4 into a host microorganism, wherein the host microorganism is Escherichia coli.
7. A recombinant formate dehydrogenase catalyst, characterized in that, The recombinant formate dehydrogenase catalyst comprises any one of the following forms: (1) Cultivate the recombinant expression transformant according to claim 5, and isolate the transformant cells containing the formate dehydrogenase mutant; (2) Cultivate the recombinant expression transformant according to claim 5, and separate the crude enzyme solution containing the formate dehydrogenase mutant; (3) Cultivate the recombinant expression transformant according to claim 5, separate the crude enzyme solution containing the formate dehydrogenase mutant, and freeze-dry the crude enzyme powder obtained; (4) Cultivate the recombinant expression transformant according to claim 5, separate the crude enzyme solution containing the formate dehydrogenase mutant, and purify the obtained pure enzyme solution.
8. A formate dehydrogenase mutant as described in claim 1 or a recombinant formate dehydrogenase catalyst as described in claim 7 in NAD + Its application in the NADH in-situ recycling system is characterized by... The formate dehydrogenase mutant or the recombinant formate dehydrogenase mutant catalyst can catalyze the oxidation of formate to CO2, while simultaneously converting NAD+ to CO2. + The NADH is reduced to NADH, and the generated NADH is used by NADH-dependent enzymes to regenerate NAD. + Formation of NAD + / NADH in-situ recycling system.
9. The application according to claim 8, characterized in that, The NADH-dependent enzyme is either cyclohexanone monooxygenase or 7β-hydroxysteroid dehydrogenase. The formate dehydrogenase mutant is coupled with cyclohexanone monooxygenase to synthesize ε-caprolactone using cyclohexanone as a substrate. The formate dehydrogenase mutant is coupled with 7β-hydroxysteroid dehydrogenase to synthesize ursodeoxycholic acid using 7-ketolithocholic acid as a substrate.
10. The application according to claim 8, characterized in that, The catalytic reaction was carried out in a phosphate buffer solution with a concentration of 0.05-0.2 mol / L and a pH of 6.0-8.0, wherein the formate was sodium formate with a concentration of 10-800 mmol / L; NAD + Concentration: 0.1-1 mmol / L; Reaction temperature: 25-50 °C o C.
Citation Information
Patent Citations
Recombinant formate dehydrogenase as well as preparation method and application thereof
CN104561052A
Formate dehydrogenase mutant with improved enzyme activity and stability as well as construction method of formate dehydrogenase mutant
CN106479988A
Formate dehydrogenase mutant with improved thermal stability and application thereof
CN113717954A
